Ashuin Kammar-García1,2, José de J Vidal-Mayo1, Juan M Vera-Zertuche3, Martín Lazcano-Hernández4, Obdulia Vera-López4, Orietta Segura-Badilla5, Patricia Aguilar-Alonso4, Addi R Navarro-Cruz4. 1. Emergency Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico. 2. Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico. 3. Department of Endocrinology, Obesity Clinic, INCMNSZ, Mexico City, Mexico. 4. Deparment of Biochemistry and Foods, Faculty of Chemical Sciences, Benemérita Universidad Autónoma de Puebla, Pue., Mexico. 5. Department of Nutrition and Public Health, Faculty of Health and Food Sciences, "Programa Universidad Bío-Bío (UBB) Saludable," Universidad del Bío-Bío, Concepción, Chile.
Abstract
BACKGROUND: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world. OBJECTIVE: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population. MATERIALS AND METHODS: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient. RESULTS: The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities. CONCLUSIONS: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients. Copyright:
BACKGROUND: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world. OBJECTIVE: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population. MATERIALS AND METHODS: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient. RESULTS: The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities. CONCLUSIONS: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients. Copyright:
Authors: J M Vera-Zertuche; J Mancilla-Galindo; M Tlalpa-Prisco; P Aguilar-Alonso; M M Aguirre-García; O Segura-Badilla; M Lazcano-Hernández; H I Rocha-González; A R Navarro-Cruz; A Kammar-García; J de J Vidal-Mayo Journal: Epidemiol Infect Date: 2021-04-29 Impact factor: 2.451
Authors: J E Salinas-Aguirre; C Sánchez-García; R Rodríguez-Sanchez; L Rodríguez-Muñoz; A Díaz-Castaño; R Bernal-Gómez Journal: Rev Clin Esp Date: 2021-01-20 Impact factor: 3.064
Authors: J Mancilla-Galindo; J M Vera-Zertuche; A R Navarro-Cruz; O Segura-Badilla; G Reyes-Velázquez; F J Tepepa-López; P Aguilar-Alonso; J de J Vidal-Mayo; A Kammar-García Journal: Epidemiol Infect Date: 2020-11-26 Impact factor: 2.451
Authors: J E Salinas-Aguirre; C Sánchez-García; R Rodríguez-Sanchez; L Rodríguez-Muñoz; A Díaz-Castaño; R Bernal-Gómez Journal: Rev Clin Esp (Barc) Date: 2021-10-05
Authors: César Esquivel-Chirino; Yolanda Valero-Princet; Luis Alberto Gaitán-Cepeda; Carlos Hernández-Hernández; Alejandro Macías Hernández; Hugo Laparra-Escareño; José Luis Ventura-Gallegos; Delina Montes-Sánchez; Ambar Lopéz-Macay; Fernando Hernández-Sánchez; William Alves de Oliveira; José Antonio Morales-González; Daniela Carmona-Ruiz; Karol Rosen-Esquivel; Alejandro Zentella-Dehesa Journal: Medicina (Kaunas) Date: 2021-12-10 Impact factor: 2.430